|1.||D'Cruz, Osmond J: 5 articles (04/2008 - 11/2003)|
|2.||Uckun, Fatih M: 5 articles (04/2008 - 11/2003)|
|3.||Uckun, F M: 3 articles (04/2001 - 01/2000)|
|4.||D'Cruz, O J: 3 articles (04/2001 - 01/2000)|
|5.||Tai, Hung-Liang: 1 article (01/2005)|
|6.||Waurzyniak, Barbara: 1 article (04/2004)|
|7.||Erbeck, Douglas: 1 article (11/2003)|
|8.||Yiv, S H: 1 article (07/2000)|
|9.||Waurzyniak, B: 1 article (07/2000)|
|10.||Venkatachalam, T K: 1 article (01/2000)|
|1.||Acquired Immunodeficiency Syndrome (AIDS)
11/01/2003 - "These findings indicated that WHI-07 shows unique clinical potential to become the active ingredient of a new female-controlled topical microbicidal vaginal contraceptive for women who are at high risk of acquiring HIV/AIDS."
01/01/2000 - "WHI-07 and its Trp analogues hold particular clinical promise for the development of novel, nondetergent-type prophylactic contraceptives for the prevention of heterosexual HIV/acquired immunodeficiency syndrome transmission."
|2.||Feline Acquired Immunodeficiency Syndrome (FAIDS)
04/01/2004 - "Collectively, using the vaginal and rectal transmucosal model for FAIDS, our studies demonstrated that WHI-07 either alone or in combination with a vanadocene has clinical potential for the development of a dual-function anti-HIV microbicide for sexually active women."
04/01/2004 - "This study evaluated whether topical application of WHI-07 as a single agent and in combination with an organometallic vanadium complex, vanadocene dithiocarbamate (VDDTC), via a nontoxic gel microemulsion can block vaginal as well as rectal transmission of feline AIDS (FAIDS) by chronically FIV-infected feline T cells in the natural host model. "
12/01/2007 - "Endpoint histology of the reproductive tract from cats and pigs after a single or repeated intravaginal exposure to WHI-07 plus VDDTC, respectively, revealed lack of irritation/inflammation in the epithelium, subepithelium/lamina propria, vessels/perivascular tissues, and underlying/surrounding muscles. "
09/01/1998 - "Unlike the intravaginal application of N-9, repetitive intravaginal application of WHI-07 did not damage the vaginal epithelium or cause local inflammation. "
12/01/2007 - "When compared with 4% N-9 (total irritation score 13-14 out of a possible 16), none of the rabbits given WHI-07 plus VDDTC intravaginally, developed histological alterations such as epithelial erosion, edema, leukocyte influx or vascular congestion characteristic of inflammation (total irritation score 4-6). "
04/01/2008 - "Based on surrogate markers for inflammation, leukocyte profile and histologic data for local tolerance, repeated intravaginal administration of WHI-07 via gel-microemulsion as a prophylactic contraceptive is unlikely to cause vaginal irritation."
12/01/2007 - "Based on comparative histologic data and surrogate markers for inflammation, repeated intravaginal administration of WHI-07 plus VDDTC via a gel-microemulsion did not result in vaginal irritation, mucosal toxicity, or systemic absorption of vanadium. "
|4.||Body Weight (Weight, Body)
11/01/2003 - "Maternal food consumption and body weight gain were unaffected by WHI-07 treatment. "
04/01/2001 - "No effects related to WHI-07 treatments were observed on survival, mean body weight, and mean body-weight gain. "
11/01/2003 - "Reproductive indices, ie, pregnancy rate, gravid uterine weights, litter size, number of corpora lutea, implantation sites, pre- and postimplantation losses, viable fetuses, resorptions, fetal body weights, and fetal sex ratio, were not affected by intravaginal exposure to WHI-07. "
|5.||Weight Loss (Weight Reduction)
|1.||Contraceptive Agents (Contraceptives)
|3.||bis(cyclopentadienyl)- N,N- diethyldithiocarbamato triflate salt
|4.||Biological Markers (Surrogate Marker)
|5.||triphosphoric acid (triphosphate)